Biosimilars unlikely to save costs as expected, experts say

Despite being heralded as lower-cost alternatives to branded biologics, the approval of biosimilar therapies for chronic diseases is not likely to yield expected cost savings due to a number of state and payer policies, according to an opinion piece published in JAMA.However, cost-savings may be attainable after key challenges to biosimilar substitution are overcome, the authors concluded.